Cargando…
Long-term effects and significant adverse drug reactions (ADRs) associated with the use of gonadotropin-releasing hormone analogs (GnRHa) for central precocious puberty: a brief review of literature
Central precocious puberty (CPP) is defined as an early pubertal development that occurs before the age of 9 years in boys and 8 years in girls. It results from premature activation of the hypothalamic-pituitary-gonadal axis. Gonadotropin-releasing hormone agonists (GnRHa) have been the gold standar...
Autores principales: | De Sanctis, Vincenzo, Soliman, Ashraf T, Di Maio, Salvatore, Soliman, Nada, Elsedfy, Heba |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mattioli 1885
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233750/ https://www.ncbi.nlm.nih.gov/pubmed/31580327 http://dx.doi.org/10.23750/abm.v90i3.8736 |
Ejemplares similares
-
Treatment of central precocious puberty using low dose GnRH analogs (GnRHa)
por: Jahagirdar, Rahul, et al.
Publicado: (2015) -
A single sample GnRHa stimulation test in the diagnosis of precocious puberty
por: Yazdani, Parvin, et al.
Publicado: (2012) -
Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty
por: Lewis, Katherine A, et al.
Publicado: (2009) -
GnRHa/Stanozolol Combined Therapy Maintains Normal Bone Growth in Central Precocious Puberty
por: Zhu, Shunye, et al.
Publicado: (2021) -
The Efficacy of GnRHa Alone or in Combination with rhGH for the Treatment of Chinese Children with Central Precocious Puberty
por: Wang, Mengjie, et al.
Publicado: (2016)